Can aminophylline reduce the need for oral corticosteroids?

Area of Science:

• Pulmonology
• Pharmacology

Background:

• Chronic obstructive airways disease (COPD) often requires long-term oral corticosteroid therapy.
• Patients on oral prednisolone for COPD frequently experience difficulties in reducing or withdrawing steroid dosage.
• Unsuccessful attempts to reduce steroid intake can lead to prolonged side effects and dependency.

Purpose of the Study:

• To evaluate the efficacy of Phyllocontin Continus in reducing oral prednisolone dosage in COPD patients.
• To assess the impact of Phyllocontin Continus on lung function parameters like FEV1 and vital capacity (VC).
• To determine the safety and tolerability of Phyllocontin Continus in this patient population.

Main Methods:

• A 33-week study involving 15 patients with long-standing COPD on oral prednisolone.
• Patients received Phyllocontin Continus (225 mg morning, 450 mg night).
• Oral prednisolone dosage reduction and lung function (FEV1, VC) were monitored.

Main Results:

• Four out of 15 patients completely withdrew from oral prednisolone.
• Seven patients achieved a beneficial reduction in steroid dosage.
• No adverse effects on FEV1 or VC were observed in patients with reduced steroid intake.
• Average daily steroid dosage decreased from 10 mg to 4.97 mg (p < 0.001).
• Mean FEV1 increased from 1.69 to 1.92 litres.

Conclusions:

• Phyllocontin Continus is effective in reducing oral prednisolone requirements for COPD patients.
• This treatment can lead to significant steroid dose reduction without compromising lung function.
• Phyllocontin Continus offers a potential therapeutic option for managing long-term steroid dependency in COPD.